|
CTLA-4 Antibody (MDX-010) Plus Interleukin-2 to Treat Advanced Melanoma Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on CTLA-4 Antibody (MDX-010) Plus Interleukin-2 to Treat Advanced Melanoma conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. CTLA-4 Antibody (MDX-010) Plus Interleukin-2 to Treat Advanced Melanoma Clinical research trials and CTLA-4 Antibody (MDX-010) Plus Interleukin-2 to Treat Advanced Melanoma medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including CTLA-4 Antibody (MDX-010) Plus Interleukin-2 to Treat Advanced Melanoma. CTLA-4 Antibody (MDX-010) Plus Interleukin-2 to Treat Advanced Melanoma Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a CTLA-4 Antibody (MDX-010) Plus Interleukin-2 to Treat Advanced Melanoma clinical trial. Participants oftentimes recieve the finest healthcare available for their CTLA-4 Antibody (MDX-010) Plus Interleukin-2 to Treat Advanced Melanoma condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > CTLA-4 Antibody (MDX-010) Plus Interleukin-2 to Treat Advanced Melanoma  CTLA-4 Antibody (MDX-010) Plus Interleukin-2 to Treat Advanced Melanoma
CTLA-4 Antibody (MDX-010) Plus Interleukin-2 to Treat Advanced Melanoma
For Condition: Melanoma
Status: Recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: This study will determine the highest dose of MDX-010 that can safely be given in conjunction with interleukin2 (IL-2) to patients with advanced melanoma, and to examine its effectiveness against the cancer. MDX-010 is designed to increase immunity to cancer. It is a laboratory-produced antibody to the CTLA-4 protein found on certain lymphocytes (a type of white blood cell). When lymphocytes recognize a foreign substance, such as a virus or bacteria, they initiate an immune response to fight and control the infection. Once this is achieved, CTLA-4 proteins help stop the immune response, decreasing the number of immune cells against the virus or bacteria. When an immune response is mounted against tumor cells, however, it may be beneficial not to stop the immune response, but instead, to keep a large number of lymphocytes available to recognize and fight tumor cells. In this study, MDX-010 will be used to block CTLA-4 and maintain immune activity. IL-2 is a naturally occurring substance whose main function is to signal immune cells to become active. FDA has approved IL-2 for treating patients with advanced melanoma and kidney cancer. Patients 16 years of age and older with stage IV melanoma (melanoma that has spread to the lymph nodes or other sites) and whose tumor is not responding to standard treatments may be eligible for this study. Each candidate will be screened with a history, physical examination, blood test, and electrocardiogram (EKG). X-rays and scans will be done to evaluate the size and extent of their tumor, if current ones are not available. Participants will receive up to four MDX-010 treatments 21 days apart. Each treatment consists of a dose of MDX-010 given intravenously (through a vein) via a catheter (thin plastic tube) over 90 minutes. IL-2 will also be given after the second and third injection of MDX-010 through a small catheter over a 15-minute period every 8 hours for as many doses as are tolerated. In addition to treatment, patients will have the following tests and procedures: - Blood tests before and during the first injection of MDX-010 and blood tests before, during and for 6 days after the second injections of MDX-010 to measure levels of the antibody, and then blood tests every 21 days (every treatment visit) to examine the body's reaction to the treatment. -Leukapheresis to study the effects of treatment on the immune system. For this procedure, blood is drawn through a needle in an arm vein and circulated through a machine that separates the blood into its components (red cells, white cells, platelets, and plasma). The lymphocytes are extracted and the rest of the blood is returned to the patient through a needle in the other arm. Leukapheresis is done just before beginning treatment and may be repeated about three weeks after the fourth treatment. - Biopsy of normal skin and tumor or lymph node to examine the effects of antibody on the immune cells in the tumor. For this procedure, a needle is put into the skin or tumor and a small amount of tissue is pulled out with the needle. Biopsies are optional; they are not required for participation in the study. - Follow-up visit 3 weeks after the fourth treatment for a checkup examination, scans and X-rays, and blood tests. Patients will be watched closely for treatment side effects. Those who develop severe drug side effects, whose bodies develop an immune reaction against the MDX-010 antibody, or whose conditions worsen during treatment may be withdrawn from the study. Those whose tumors have stabilized or shrunk will continue follow-up visits.
Details: This is an open-label study of a human monoclonal antibody (mAb) to CTLA-4 (MDX-010) administered with interleukin-2 to patients with measurable metastatic melanoma who have not previously received high dose IL-2. Patients will be enrolled to escalating dose levels of MDX-010 given in combination with high-dose IL-2 to determine the maximally tolerated dose. When the MTD is determined, the efficacy will be assessed in a standard Phase II fashion.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Any patient greater than or equal to 16 years of age with a histologic diagnosis of stage IV melanoma (may include mucosal or ocular melanoma) that is clinically evaluable, with at least one site of measurable disease. Patients may not have received prior therapy with MDX-010 antibody or high-dose IL-2 (greater than or equal to 600,000 IU/kg q8h). Greater than or equal to 3 weeks since treatment (chemo-, radiation, hormone, immuno-, etc., therapy) for melanoma and recovered from any serious toxicity experienced during treatment. Women should be either: post-menopausal for at least one (1) year; surgically incapable of bearing children; or utilizing a reliable form of contraception. Women of childbearing potential must have a negative urine pregnancy test conducted during screening. Because the risk of a negative influence of this therapy on reproductive processes, men who may father a child must agree to the use of male contraception for the duration of their participation in the trial. Life expectancy greater than or equal to 3 months. ECOG Performance Status less than 2. For patients greater than 50 years of age or history of cardiovascular disease, a normal thallium stress test is required. Required values for initial laboratory test: WBC greater than or equal to 2500/ml. ANC greater than or equal to 1500/ml Platelets greater than or equal to 100 x 10(3)/ml. Hemoglobin greater than or equal to 10 g/dl. Hematocrit greater than or equal to 30%. Creatinine less than or equal to 2.0 mg/dl. AST less than or equal to 3 x ULN (unless definitely attributable to disease). Bilirubin less than or equal to 1.0 x ULN (unless definitely attributable to disease) [except patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dl]. HbsAg is negative. HIV is negative. Anti-HCV is nonreactive. EXCLUSION CRITERIA: Patients will be excluded who have any of the following: Any other prior malignancy, except for the following: adequately treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or any other cancer from which the patient has been disease-free for five (5) years or more. Autoimmune disease (including uveitis and autoimmune inflammatory eye disease) prior to the study. Active infection, this includes positive results from HIV, HbsAg and anti-HCV. Pregnancy or nursing. Any underlying medical condition which, in the opinion of the principal investigator, will make the administration of study drug hazardous or obscure the interpretation of adverse events. Any concurrent medical condition requiring the use of systemic or topical corticosteroids or the use of immunosuppressive agents (e.g. cyclosporin and its analog, or chemotherapy agents). All corticosteroid use must have been discontinued greater than or equal to four (4) weeks prior to trial entry. Prior treatment with MDX-010 or high-dose IL-2. Evidence or history of significant cardiac, pulmonary, hepatic, renal, psychiatric or gastrointestinal disease that would make the administration of high-dose IL-2 unsafe.
Total Enrollment: 51
Location and Contact Information:
National Cancer Institute (NCI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 030109; 03-C-0109
Study Start Date: February 19, 2003
Record last reviewed: January 6, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00055211
Other Melanoma Studies:
1. A Phase II Protocol of Flt3 Ligand in Patients with Metastatic Melanoma and Renal Cancer
2. Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity
3. CTLA-4 Antibody (MDX-010) Plus Interleukin-2 to Treat Advanced Melanoma
4. Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
5. Surgery vs. Chemotherapy in Patients with Stage IV Melanoma
Related Studies:
Other Melanoma Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
CTLA-4 Antibody (MDX-010) Plus Interleukin-2 to Treat Advanced Melanoma
|
|
|
|
|
|
|
|
